Carbamazepine dose-frequency requirement in children

Area of Science:

• Pediatric Pharmacology
• Clinical Pharmacy
• Pharmacokinetics

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug in children.
• Understanding optimal dosing regimens is crucial for efficacy and safety.
• Daily fluctuations in drug levels can impact treatment outcomes.

Purpose of the Study:

• To investigate the dose-frequency requirements for carbamazepine in pediatric patients.
• To determine the impact of different dosing frequencies on daily fluctuations in CBZ saliva concentrations.
• To correlate drug levels with toxic features and therapeutic range adherence.

Main Methods:

• Serial saliva samples were collected from 6 children (6-13 years) in a steady state.
• Carbamazepine concentrations were measured under two different dose-frequency regimens.
• Pharmacokinetic parameters, including half-life and volume of distribution, were analyzed.

Main Results:

• More frequent dosing resulted in smaller fluctuations in saliva carbamazepine concentrations.
• A shorter time with drug levels outside the therapeutic range was observed with optimized frequency.
• Toxic features and convulsions correlated with peak and trough concentrations, not total dose.
• Saliva CBZ half-lives ranged from 7.3 to 12.7 hours.

Conclusions:

• Saliva carbamazepine concentrations provide a convenient method for individualizing pediatric dosage.
• Optimizing dosing frequency is key to minimizing fluctuations and improving therapeutic drug monitoring.
• Pharmacokinetic data from saliva samples support rational prescribing of carbamazepine in children.